Phase I trial of ISIS-ANGPTL3Rx in healthy volunteers.
Latest Information Update: 25 Mar 2015
At a glance
- Drugs IONIS ANGPTL3Rx (Primary)
- Indications Hyperlipidaemia
- Focus Adverse reactions
- Sponsors Isis Pharmaceuticals
- 23 Mar 2015 Results were presented at the were presented at the 83rd European Atherosclerosis Society in Glasgow, according to an Isis Pharmaceuticals media release.
- 23 Mar 2015 Results published in Isis Pharmaceuticals media release.
- 23 Mar 2015 Status changed from recruiting to completed, according to an Isis Pharmaceuticals media release.